ENMD-981693
As of the edition of 20 October 2026, ENMD-981693 is a small molecule: went quiet in 2012; acts on AURKA, BLK and FGFR1 and 16 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2012
- Kind
- Small molecule
- Registered trials
- 9, 0 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Blood and lymph; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
19 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product19 company-target rows are on route A because of ENMD-981693.
See the 19 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| AURKA | Aurora kinase A | O14965 |
| LCK | Tyrosine-protein kinase Lck | P06239 |
| FYN | Tyrosine-protein kinase Fyn | P06241 |
| YES1 | Tyrosine-protein kinase Yes | P07947 |
| LYN | Tyrosine-protein kinase Lyn | P07948 |
| HCK | Tyrosine-protein kinase HCK | P08631 |
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| FGR | Tyrosine-protein kinase Fgr | P09769 |
| FGFR1 | Fibroblast growth factor receptor 1 | P11362 |
| SRC | Proto-oncogene tyrosine-protein kinase Src | P12931 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FGFR2 | Fibroblast growth factor receptor 2 | P21802 |
| FGFR4 | Fibroblast growth factor receptor 4 | P22455 |
| FGFR3 | Fibroblast growth factor receptor 3 | P22607 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | P36888 |
| FRK | Tyrosine-protein kinase FRK | P42685 |
| BLK | Tyrosine-protein kinase Blk | P51451 |
| SRMS | Tyrosine-protein kinase Srms | Q9H3Y6 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 5 | 5 | 0 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| CASI pharmaceuticals | Lead sponsor of trials | 2006 to now |